See more : Fideicomiso Irrevocable db/1616 (FINN13.MX) Income Statement Analysis – Financial Results
Complete financial analysis of LIGAND PHARMACEUTICAL INC (LGNXZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of LIGAND PHARMACEUTICAL INC, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
You may be interested
- Viaplay Group AB (publ) (NENT-A.ST) Income Statement Analysis – Financial Results
- East Tender Optoelectronics Corporation (6588.TWO) Income Statement Analysis – Financial Results
- Ramkrishna Forgings Limited (RKFORGE.BO) Income Statement Analysis – Financial Results
- Bolsa Mexicana de Valores, S.A.B. de C.V. (BOMXF) Income Statement Analysis – Financial Results
- Forest Water Environmental Engineering Co., Ltd. (8473.TW) Income Statement Analysis – Financial Results
LIGAND PHARMACEUTICAL INC (LGNXZ)
About LIGAND PHARMACEUTICAL INC
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 131.31M | 196.25M | 241.54M | 186.42M | 120.28M | 251.45M | 141.10M | 108.97M | 71.91M | 64.54M | 48.97M | 31.39M | 30.04M | 23.54M | 38.94M | 27.32M | 12.89M | 140.96M | 176.61M | 81.12M | 141.14M | 96.64M |
| Cost of Revenue | 43.29M | 77.10M | 96.27M | 56.14M | 53.58M | 22.13M | 17.49M | 16.21M | 5.81M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 22.64M | 39.85M | 26.56M | 31.62M | 20.31M |
| Gross Profit | 88.03M | 119.15M | 145.27M | 130.28M | 66.70M | 229.32M | 123.62M | 92.76M | 66.11M | 64.54M | 48.97M | 31.39M | 30.04M | 23.54M | 38.94M | 27.32M | 12.89M | 118.32M | 136.76M | 54.56M | 109.52M | 76.33M |
| Gross Profit Ratio | 67.03% | 60.71% | 60.14% | 69.89% | 55.45% | 91.20% | 87.61% | 85.12% | 91.93% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 83.94% | 77.44% | 67.26% | 77.60% | 78.99% |
| Research & Development | 25.42M | 36.25M | 32.23M | 57.12M | 30.54M | 27.86M | 26.89M | 21.22M | 13.38M | 6.06M | 6.32M | 7.88M | 8.70M | 16.26M | 30.61M | 7.00M | 1.49M | 3.98M | 10.53M | 14.01M | 26.51M | 42.12M |
| General & Administrative | 0.00 | 0.00 | 57.48M | 64.44M | 41.88M | 37.73M | 28.65M | 26.62M | 24.38M | 22.57M | 17.98M | 16.11M | 14.98M | 12.83M | 15.21M | 23.79M | 30.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | -10.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 52.79M | 70.06M | 46.79M | 64.44M | 41.88M | 37.73M | 28.65M | 26.62M | 24.38M | 22.57M | 17.98M | 16.11M | 14.98M | 12.83M | 15.21M | 23.79M | 30.41M | 79.75M | 74.66M | 52.54M | 51.66M | 41.68M |
| Other Expenses | 0.00 | 0.00 | 9.57M | 53.86M | 0.00 | 0.00 | 12.12M | 11.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 206.48M | 78.05M | 62.03M | 50.53M | 16.69M |
| Operating Expenses | 78.21M | 106.31M | 79.02M | 121.55M | 72.42M | 65.60M | 55.54M | 47.84M | 37.76M | 28.63M | 24.30M | 23.99M | 23.68M | 29.09M | 45.82M | 30.79M | 31.90M | 290.21M | 163.23M | 128.58M | 128.70M | 100.49M |
| Cost & Expenses | 121.49M | 183.41M | 175.29M | 177.69M | 126.00M | 87.73M | 73.03M | 64.06M | 43.57M | 44.91M | 34.03M | 30.81M | 32.44M | 54.54M | 70.76M | 126.56M | 75.03M | 312.85M | 203.08M | 155.14M | 160.32M | 120.79M |
| Interest Income | 7.71M | 2.05M | 886.00K | 8.08M | 28.43M | 14.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 31.00K | 440.00K | 586.00K | 2.16M | 8.66M | 3.78M | 1.89M | 783.00K | 783.00K | 1.09M |
| Interest Expense | 656.00K | 1.80M | 19.62M | 27.42M | 35.75M | 48.28M | -11.40M | -12.18M | -11.80M | -4.86M | -2.08M | -3.31M | 2.51M | 58.00K | 270.00K | 202.00K | 735.00K | 10.61M | 12.46M | 12.34M | -10.97M | -6.30M |
| Depreciation & Amortization | 37.41M | 43.39M | 41.34M | 27.97M | 43.73M | 16.69M | 12.52M | 11.29M | 2.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | 101.73M | 56.23M | 133.16M | 44.85M | 876.12M | 238.30M | 81.15M | 31.43M | 49.76M | 18.82M | 13.95M | 574.00K | -698.00K | -13.13M | -9.97M | -97.28M | -50.11M | -168.77M | -26.47M | -18.27M | -19.18M | -24.15M |
| EBITDA Ratio | 77.47% | 28.65% | 44.54% | 19.69% | 31.60% | 71.75% | 57.12% | 51.58% | 43.07% | 30.41% | 30.51% | 1.83% | -2.32% | -124.50% | -25.60% | -356.13% | -466.69% | -119.73% | -14.99% | -91.25% | -13.59% | -24.99% |
| Operating Income | 9.82M | 12.84M | 66.25M | 8.73M | -5.72M | 163.73M | 68.08M | 44.92M | 28.35M | 19.63M | 14.94M | 574.00K | -698.00K | -29.30M | -9.97M | -97.28M | -60.18M | -168.77M | -26.47M | -74.02M | -19.18M | -24.15M |
| Operating Income Ratio | 7.48% | 6.54% | 27.43% | 4.68% | -4.76% | 65.11% | 48.25% | 41.22% | 39.42% | 30.41% | 30.51% | 1.83% | -2.32% | -124.50% | -25.60% | -356.13% | -466.69% | -119.73% | -14.99% | -91.25% | -13.59% | -24.99% |
| Total Other Income/Expenses | 53.84M | 23.17M | 5.95M | -19.27M | -10.44M | 9.60M | -10.85M | -36.96M | 6.98M | -8.32M | -5.74M | -4.44M | -2.86M | 13.90M | 95.00K | -239.00K | 6.72M | -5.50M | -9.87M | 29.11M | -18.28M | -8.45M |
| Income Before Tax | 63.66M | 36.01M | 72.21M | -10.54M | 796.64M | 173.33M | 57.23M | 7.96M | 35.33M | 11.30M | 9.21M | -3.87M | -2.95M | -15.40M | -9.87M | -97.52M | -53.46M | -174.27M | -36.34M | -94.41M | -37.46M | -32.60M |
| Income Before Tax Ratio | 48.48% | 18.35% | 29.89% | -5.65% | 662.31% | 68.93% | 40.56% | 7.30% | 49.13% | 17.51% | 18.80% | -12.31% | -9.83% | -65.44% | -25.35% | -357.00% | -414.58% | -123.63% | -20.58% | -116.39% | -26.54% | -33.73% |
| Income Tax Expense | 9.84M | 41.23M | -4.15M | -7.55M | 167.34M | 30.01M | 44.68M | 10.33M | -192.12M | -410.00K | -374.00K | -1.51M | -13.13M | 2.62M | -7.92M | 392.00K | -22.77M | 38.41M | -59.00K | -56.00K | 0.00 | 0.00 |
| Net Income | 52.15M | -33.36M | 57.14M | -2.99M | 629.30M | 143.32M | 12.56M | -2.37M | 229.82M | 11.71M | 11.42M | -2.36M | 10.18M | -10.37M | -1.95M | -98.11M | 281.69M | -212.69M | -36.40M | -96.47M | -37.46M | -32.60M |
| Net Income Ratio | 39.72% | -17.00% | 23.66% | -1.60% | 523.19% | 57.00% | 8.90% | -2.17% | 319.58% | 18.15% | 23.32% | -7.51% | 33.88% | -44.07% | -5.00% | -359.19% | 2,184.64% | -150.88% | -20.61% | -118.93% | -26.54% | -33.73% |
| EPS | 3.02 | -1.98 | 3.44 | -0.18 | 33.13 | 6.77 | 0.60 | -0.11 | 11.61 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 2.94 | -1.98 | 3.31 | -0.18 | 31.85 | 5.96 | 0.53 | -0.11 | 10.83 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 17.30M | 16.87M | 16.63M | 16.18M | 19.00M | 21.16M | 21.03M | 20.83M | 19.79M | 20.42B | 20.31B | 19.85B | 19.66B | 19.61B | 113.18B | 95.51B | 98.12B | 80.62B | 74.02B | 70.69B | 70.69B | 69.12B |
| Weighted Avg Shares Out (Dil) | 17.76M | 16.87M | 17.25M | 16.18M | 19.76M | 24.07M | 23.48M | 20.83M | 21.23M | 21.43B | 20.75B | 19.85B | 19.71B | 19.61B | 113.18B | 95.51B | 98.12B | 80.62B | 74.02B | 70.69B | 70.69B | 69.12B |
No news found for: LGNXZ
Source: https://incomestatements.info
Category: Stock Reports